BioTrove Withdraws IPO Registration | GenomeWeb
NEW YORK (GenomeWeb News) – BioTrove has asked the US Securities and Exchange Commission to consent to the firm’s withdrawal of its registration statement for an initial public offering of common stock.
 
The Woburn, Mass.-based genomics research instrument developer said in its letter to the SEC yesterday that it is withdrawing the offering due to “unfavorable market conditions that would adversely affect the offering of the shares of common stock.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.